Clinical and microbiological profile of health care associated pneumonia in patients with chronic renal disease referred to a tertiary care hospital- a prospective study
Abstract
Background: Healthcare associated pneumonia (HCAP) is a public health problem in the era of home care of chronic illness including chronic renal disease. They have greater burden of comorbidities, immune suppression and impaired mobility.
Aim of the Study: To characterise the clinical, radiological and microbiological profile of health care associated pneumonia in chronic renal disease cases including its resistance pattern and outcome in the study population.
Materials and Methods: This prospective study was conducted among patients with chronic kidney disease (CKD) who had been treated in multiple hospitals across Odisha. They were subjected to history taking, clinical examination, laboratory and radiological investigations. Sputum or endotracheal tube culture were sent for gram stain and aerobic culture. All the categorical parameters were compared using Fisher’s exact test. Continuous parameters were compared using independent t-test. All the statistical analysis was carried out using the software Stata 15.1. A p-value less than 0.05 was considered significant.
Results: 58 patients with an underlying chronic kidney disease were included. 54 (93.1%%) patients survived while 4 (6.9%) died. The mean age, total leucocyte count and serum urea levels were higher among patients who died in comparison to the survivors (p= 0.95, 0.334 and 0.386 respectively). Klebsiella spp (12.07%), and Acinetobacter (8.6%) were most commonly isolated. Multi-drug resistance (MDR) and extensive drug resistance (XDR) were encountered among these organisms. Death was more commonly associated in patients ≥60yrs (p= 1), TLC ≥ 11000 cells/mm3 (p= 0.0091), serum creatinine ≥ 3mg/dl (p= 0.329) and radiological involvement of ≥ 3zones (p= 1).
Conclusion: CKD is an important contributor in HCAP. Data from different institutions to corroborate our findings regarding antibiotic resistance pattern of the microbes in HCAP cases is recommended.
Downloads
References
2. Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4(5):e307-19. doi: 10.1016/S2214-109X(16)00071-1.
3. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Resp Crit Care Med. 2005;171(4):388-416. doi:https://doi.org/10.1164/rccm.200405-644ST
4. Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Combating Antimicrobial Resistance: Policy Recommendations to Save Lives. Clinic Infect Dis. 2011;52(suppl_5):S397-S428. doi: 10.1093/cid/cir153
5. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14. doi: 10.1086/668770. Epub 2012 Nov 27.
6. Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004;164(5):502-508. doi:10.1001/archinte.164.5.502
7. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006;70(6):1135-1141. Epub 2006 Jul 26. doi:10.1038/sj.ki.5001714
8. Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients--the United States Renal Data System. Nephrol Dial Transplant. 2008;23(2):680-686. Epub 2007 Nov 19. doi:10.1093/ndt/gfm474
9. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009;135(3):633-640. doi: 10.1378/chest.08-1357. Epub 2008 Nov 18.
10. Carratalà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R, Manresa F, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007;167(13):1393-1399. doi:10.1001/archinte.167.13.1393.
11. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrobial agents and chemotherapy. 2007;51(10):3568-3573. doi: 10.1128/AAC.00851-07
12. Falcone M, Venditti M, Shindo Y, Kollef MH. Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia. Int J Infect Dis. 2011;15(8):e545-550. doi: 10.1016/j.ijid.2011.04.005. Epub 2011 May 26.
13. Venditti M, Falcone M, Corrao S, Licata G, Serra P; Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150(1):19-26. doi:10.7326/0003-4819-150-1-200901060-00005
14. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemo. 2001;45(4):1151-1161. doi: 10.1128/AAC.45.4.1151-1161.2001
15. Hossain A, Ferraro MJ, Pino R, Dew RB, Moland ES, Lockhart TJ, Thomson KS, Goering RV, Hanson ND. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemo. 2004;48(11):4438-4440. doi: 10.1128/AAC.48.11.4438-4440.2004
16. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460-469. doi: 10.1080/21505594.2016.1222343. Epub 2016 Aug 11.
17. Quale JM, Landman D, Bradford PA, Visalli M, Ravishankar J, Flores C, et al. Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis. 2002;35(7):834-841. Epub 2002 Sep 10. doi:10.1086/342577
18. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854-3862. doi:10.1378/chest.128.6.3854
19. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000 ;31(1):101-106. Epub 2000 Jul 17. doi:10.1086/313902
20. Shrivastava SR, Shrivastava PS, Ramasamy J. World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. J Med Soc. 2018;32(1):76-77. doi: 10.4103/jms.jms_25_17
21. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis. 2011;53(2):107-113. doi: 10.1093/cid/cir274.
22. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012;54(4):470-478. doi: 10.1093/cid/cir840. Epub 2011 Nov 21.
23. Durlach R, McIlvenny G, Newcombe RG, Reid G, Doherty L, Freuler C, et al. Prevalence survey of healthcare-associated infections in Argentina; comparison with England, Wales, Northern Ireland and South Africa. J Hosp Infect. 2012;80(3):217-223. doi: 10.1016/j.jhin.2011.12.001. Epub 2012 Jan 9.
24. Salgado Yepez E, Bovera MM, Rosenthal VD1, González Flores HA, Pazmiño L, Valencia F, et al. Device-associated infection rates, mortality, length of stay and bacterial resistance in intensive care units in Ecuador: International Nosocomial Infection Control Consortium's findings. World J Biol Chem. 2017;8(1):95-101. doi: 10.4331/wjbc.v8.i1.95.
25. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). (2017). Kidney International Supplements, 7(1), pp.1-59.
OAI - Open Archives Initiative
